Quick Answer
Cadrenal Therapeutics, Inc. reported Cash and Equivalents of $4.01 million for fiscal year 2025.
Cadrenal Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $4.01M | -60.0% |
| 2024 | $10.02M | +19.2% |
| 2023 | $8.40M | +25685.6% |
| 2022 | $32.6K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.86M | — | -22.8% |
| July 31, 2025 | $5.00M | — | -10.2% |
| June 30, 2025 | $5.57M | — | -24.1% |
| March 31, 2025 | $7.34M | +11.7% | -26.8% |
| December 31, 2024 | $10.02M | +19.2% | +52.6% |
| March 31, 2024 | $6.57M | — | -21.9% |
| December 31, 2023 | $8.40M | +25685.6% | -7.8% |
| September 30, 2023 | $9.11M | — | +27855.1% |
- Cadrenal Therapeutics, Inc. showed a decrease of -60.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, Cadrenal Therapeutics, Inc.’s cash and equivalents has grown by 12199.1% (from $32.6 thousand to $4.01 million).
- The most recent figure is from Cadrenal Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: